Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Company profile
Ticker
CHMA
Exchange
Website
CEO
Raj Kannan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHIASMA INC
SEC CIK
Corporate docs
Subsidiaries
Chiasma (Israel) Ltd. • Chiasma Securities Corp ...
CHMA stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
12 Aug 21
15-12B
Securities registration termination
11 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Aug 21
POS AM
Prospectus update (post-effective amendment)
6 Aug 21
8-K
Appoints Raj Kannan and Dr. Roni Mamluk as Non-Executive Directors
5 Aug 21
25-NSE
Exchange delisting
5 Aug 21
Transcripts
CHMA
Earnings call transcript
2020 Q4
5 Mar 21
CHMA
Earnings call transcript
2020 Q3
8 Nov 20
CHMA
Earnings call transcript
2020 Q2
10 Aug 20
CHMA
Earnings call transcript
2020 Q1
11 May 20
CHMA
Earnings call transcript
2019 Q4
16 Mar 20
CHMA
Earnings call transcript
2019 Q3
6 Nov 19
CHMA
Earnings call transcript
2019 Q2
10 Aug 19
CHMA
Earnings call transcript
2019 Q1
12 May 19
Latest ownership filings
SC 13G/A
Rock Springs Capital Management LP
15 Feb 22
4
Change in insider ownership
9 Aug 21
SC 13G/A
Stonepine Capital Management, LLC
9 Aug 21
4
WILLIAM LUDLAM
5 Aug 21
4
Roni Mamluk
5 Aug 21
4
Scott Minick
5 Aug 21
4
JOHN A SCARLETT
5 Aug 21
4
DAVID M STACK
5 Aug 21
4
JOHN F THERO
5 Aug 21
4
Anand Varadan
5 Aug 21
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.85 mm | 44.85 mm | 44.85 mm | 44.85 mm | 44.85 mm | 44.85 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.17 mm | 7.49 mm | 6.88 mm | 6.95 mm |
Cash used (since last report) | n/a | n/a | 374.60 mm | 276.02 mm | 253.58 mm | 256.05 mm |
Cash remaining | n/a | n/a | -329.75 mm | -231.17 mm | -208.74 mm | -211.20 mm |
Runway (months of cash) | n/a | n/a | -32.4 | -30.9 | -30.3 | -30.4 |
Institutional ownership, Q1 2023
12.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 30.97 mm |
Total shares | 7.12 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MPM BioVentures IV QP | 7.12 mm | $30.97 mm |